TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: HIVPR    
HIV-1 Genotypic Drug Resistance to Protease and Reverse Transcriptase Inhibitors, Plasma

Method Description Describes how the test is performed and provides a method-specific reference

This assay utilized a modified method involving the use of the FDA-approved ViroSeq HIV-1 Genotyping System v2.0. HIV-1 RNA in a given human plasma specimen is extracted and purified by a manual method. The entire protease gene from codons 1 to 99 and two-thirds of the reverse transcriptase (RT) gene from codons 1 to 335 of the HIV-1 genome present in plasma are amplified and sequenced with 7 sequencing reactions in forward and reverse directions with the AB 3500xL genetic analyzer. The sequence data generated for the patient's HIV-1 virus are assembled, edited, and analyzed with the ViroSeq HIV-1 Genotyping System Software v3 per manufacturer's instructions. The consensus sequence assembled is compared to a known reference (wild-type) HIV-1 strain sequence to determine the presence of all resistance-related mutation codons using the Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra). The mutation codons observed are compared to the known list of HIV-1 genotypic drug resistance mutations and interpreted for susceptibility to the corresponding antiretroviral drugs.(Package insert: ViroSeq HIV-1 Genotyping System v2.0; Abbott Molecular, Inc., Des Plaines, IL. 04/2016; Unpublished Mayo method)

PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Varies

Report Available The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 10 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

2 months

Performing Laboratory Location Indicates the location of the laboratory that performs the test

Rochester